Page 199 - 2020_07-Haematologica-web

Lenalidomide-based regimens in elderly MM
AB
CD
EF
Figure 2. Post-hoc analysis according to frailty status in patients treated with different induction treatments. (A, B) Progression-free survival (PFS) (A) and overall survival (OS) (B) in fit patients according to treatment arm. (C, D) PFS (C) and OS (D) in intermediate-fit patients according to treatment arm. (E; F) PFS (E) and OS (F) in frail patients according to treatment arm. All time to events were calculated from the time of random assignment to induction treatment arms. MPR: melpha- lan-prednisone-lenalidomide; CPR: cyclophosphamide-prednisone-lenalidomide; Rd: lenalidomide-dexamethasone; HR: hazard ratio; CI: confidence interval; P: P value.
haematologica | 2020; 105(7)
1941